Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ritlecitinib Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 367,105Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1792180-81-4, Pf-06651600, Ritlecitinib, 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, 2oye00pc25, Pf-06651600 free base
    Molecular Formula
    C15H19N5O
    Molecular Weight
    285.34  g/mol
    InChI Key
    CBRJPFGIXUFMTM-WDEREUQCSA-N
    FDA UNII
    2OYE00PC25
    Ritlecitinib is an orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
    2.1.2 InChI
    InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
    2.1.3 InChI Key
    CBRJPFGIXUFMTM-WDEREUQCSA-N
    2.1.4 Canonical SMILES
    CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
    2.1.5 Isomeric SMILES
    C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
    2.2 Other Identifiers
    2.2.1 UNII
    2OYE00PC25
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(5-((7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

    2. Pf-06651600

    2.3.2 Depositor-Supplied Synonyms

    1. 1792180-81-4

    2. Pf-06651600

    3. Ritlecitinib

    4. 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

    5. 2oye00pc25

    6. Pf-06651600 Free Base

    7. 1-[(2s,5r)-2-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

    8. Pf06651600

    9. Pf 06651600

    10. Ritlecitinib?

    11. 2-propen-1-one, 1-((2s,5r)-2-methyl-5-(7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-1-piperidinyl)-

    12. Ritlecitinib [inn]

    13. Unii-2oye00pc25

    14. Ritlecitinib [who-dd]

    15. Gtpl9559

    16. Chembl4085457

    17. Schembl16764638

    18. Bcp24778

    19. Ex-a2613

    20. Example 5 [wo2015083028]

    21. Zinc526061581

    22. Ccg-267324

    23. Db14924

    24. Compound 11 [pmid: 28139931]

    25. Ac-35550

    26. Bp168506

    27. Hy-100754

    28. Cs-0020243

    29. S8538

    30. C91239

    31. Pf06651600;pf 06651600

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 285.34 g/mol
    Molecular Formula C15H19N5O
    XLogP32.1
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count3
    Exact Mass285.15896025 g/mol
    Monoisotopic Mass285.15896025 g/mol
    Topological Polar Surface Area73.9 Ų
    Heavy Atom Count21
    Formal Charge0
    Complexity402
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of alopecia areata